We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+30.41%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$312M
AUM Growth
+$177M
Cap. Flow
+$129M
Cap. Flow %
41.38%
Top 10 Hldgs %
97.81%
Holding
15
New
1
Increased
–
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$145M

Top Sells

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$15.9M
2
EGLT
Egalet Corporation
EGLT
+$7K

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
1
Gossamer Bio
GOSS
$66.5M
$151M 48.31%
+6,953,416
New +$145M
REPL icon
2
Replimune Group
REPL
$814M
$77.4M 24.82%
5,103,455
– –
TBIO
3
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$24.8M 7.96%
2,437,603
– –
PRTK
4
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$13.9M 4.47%
2,600,410
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$12.8M 4.1%
999,364
– –
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$7.32M 2.35%
551,477
– –
KYNB
7
Kyntra Bio
KYNB
$28.5M
$7.1M 2.28%
5,226
– –
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$4M 1.28%
75,440
– –
EPIX
9
DELISTED
ESSA Pharma
EPIX
$3.7M 1.19%
1,084,848
– –
JNCE
10
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.29M 1.05%
529,965
– –
PVLA
11
Palvella Therapeutics
PVLA
$1.98B
$2.61M 0.84%
9,728
– –
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.45M 0.79%
167,157
– –
SNNA
13
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
$1.76M 0.56%
758,610
– –
KZR
14
DELISTED
Kezar Life Sciences
KZR
– –
-67,562
Closed -$15.9M
EGLT
15
DELISTED
Egalet Corporation
EGLT
– –
-2,889,926
Closed -$7K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2019 Portfolio in Review

As of Q1 2019, Omega Fund Management held 15 positions worth $312M, up 131% from $135M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Omega Fund Management deployed $129M of net new capital in Q1 2019, opening 1 new position. Its largest new stake was Gossamer Bio: 6,953,416 shares worth $151M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

On the sell side, the most notable exit was Kezar Life Sciences, an estimated $15.9M sold.

  • Omega Fund Management's largest Q1 2019 buy was Gossamer Bio: 6,953,416 shares worth $151M.
  • Omega Fund Management fully exited Kezar Life Sciences in Q1 2019, selling an estimated $15.9M.
  • Omega Fund Management's ten largest holdings make up 98% of its $312M portfolio in Q1 2019.
  • Omega Fund Management opened 1 new position and closed 2 in Q1 2019.
  • Omega Fund Management's portfolio value rose 131% quarter-over-quarter to $312M.

Based on Omega Fund Management's 13F filing for Q1 2019, filed 15 May 2019.